APOMORPHINE - SUBLINGUAL (Kynmobi®)
Clinical Indication
Idiopathic Parkinson’s Disease
Date of classification
June 2026
Orange
Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.